Rectal cancer is diagnosed through a combination of physical examination, colonoscopy with biopsy, and imaging studies that determine how far the cancer has spread. The process typically starts when a screening test or symptom prompts a closer look, and a tissue sample from colonoscopy provides the definitive answer. What follows the biopsy is a series of scans and lab work that classify the tumor’s size, depth, and whether it has reached nearby or distant organs.
How Rectal Cancer Is First Detected
Most rectal cancers are caught one of two ways: routine screening or investigation of symptoms. The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults aged 45 to 75. Screening options include a stool-based test (FIT) done every year or a colonoscopy every 10 years. If either test turns up something abnormal, a diagnostic colonoscopy follows.
Symptoms that trigger evaluation include rectal bleeding, a persistent change in bowel habits (narrower stools, a feeling of incomplete emptying), unexplained weight loss, or pelvic pain. These symptoms overlap heavily with common benign conditions like hemorrhoids and anal fissures, which is exactly why doctors don’t rely on symptoms alone. Any rectal bleeding or bowel changes lasting longer than two weeks warrant evaluation.
The Physical Exam
A digital rectal exam is often the first hands-on step. A clinician inserts a gloved finger into the rectum and feels along the rectal wall for masses, nodules, or areas of unusual firmness. Because the rectum is only about 12 to 15 centimeters long, a tumor in the lower or mid-rectum can sometimes be felt directly. The exam also checks for blood, pain, or any physical obstruction. A digital rectal exam alone cannot diagnose cancer, but it can raise suspicion and guide the next steps.
Colonoscopy and Biopsy
Colonoscopy is the key diagnostic procedure. A flexible camera is guided through the entire colon and rectum, giving a direct view of any abnormal growths. If a mass or suspicious polyp is found, the doctor takes a tissue sample (biopsy) during the same procedure. This biopsy is sent to a pathologist who examines the cells under a microscope to confirm whether cancer is present and, if so, what type.
Beyond confirming cancer, the biopsy tissue undergoes molecular testing. The College of American Pathologists recommends that all colorectal cancer samples be tested for mismatch repair (MMR) protein status or microsatellite instability (MSI). These tests look at whether the tumor’s DNA repair system is functioning normally. A tumor with deficient DNA repair, called “MSI-high,” responds well to certain immunotherapy drugs and may also signal Lynch syndrome, an inherited condition that raises the risk of several cancers. This molecular information directly shapes treatment decisions, so it is now considered standard for every patient.
MRI for Local Staging
Once a biopsy confirms rectal cancer, a pelvic MRI is the most important imaging study for understanding what’s happening locally. MRI provides exceptional soft-tissue detail, allowing radiologists to assess three critical factors: how deep the tumor has grown into or through the rectal wall, whether nearby lymph nodes appear involved, and how close the tumor sits to the surrounding tissue envelope called the mesorectal fascia.
The distance between the tumor and the mesorectal fascia matters enormously. This thin boundary layer is what surgeons aim to cut around during an operation. If the tumor is too close to or has already reached this fascia, the risk of the cancer returning locally after surgery is significantly higher, and the patient will likely need radiation and chemotherapy before any operation. Radiologists measure this distance in millimeters on the MRI and report it as part of the staging workup.
MRI also pinpoints where the tumor sits relative to the anal opening. Tumors in the lower rectum (within about 5 centimeters of the anal opening) behave differently, often responding more strongly to pre-surgical radiation but also posing greater surgical challenges for preserving normal bowel function.
Endorectal Ultrasound for Early Tumors
For tumors that appear small and confined to the rectal wall, endorectal ultrasound (ERUS) offers an additional layer of detail. A small ultrasound probe is inserted into the rectum and produces high-resolution images of the individual layers of the rectal wall. This helps distinguish between a tumor limited to the inner lining (T1) and one that has grown into the muscle layer (T2), a distinction that determines whether a patient might qualify for a less invasive local excision instead of major surgery.
ERUS is highly accurate for distinguishing early from advanced tumors, with reported accuracy around 94% for that broad classification. Its ability to correctly identify the specific T stage ranges from 88% to 95% in published studies, and it tends to outperform MRI for these early-stage assessments. However, ERUS has limited value for larger or more advanced tumors, where MRI is the preferred tool.
CT Scans for Distant Spread
While MRI handles the local picture, CT scanning is used to check whether the cancer has spread to distant organs. The American College of Radiology recommends a contrast-enhanced CT of the chest, abdomen, and pelvis as the standard initial imaging for distant staging. An alternative is a CT of the chest combined with an MRI of the abdomen. The lungs and liver are the most common sites of rectal cancer metastasis, so these scans focus heavily on those organs.
Only one of these imaging combinations is typically needed. The choice depends on what’s already been done and what information is still missing. If a pelvic MRI has already been completed for local staging, a separate CT of the chest and abdomen may be sufficient.
Blood Tests: What They Can and Cannot Do
A blood marker called CEA (carcinoembryonic antigen) is commonly drawn during the diagnostic workup, but it is not useful for detecting rectal cancer in the first place. CEA has poor sensitivity for early-stage disease: only about 3% of the earliest-stage cancers produce elevated CEA levels, compared to roughly 56% of the most advanced cases. Many benign conditions can also raise CEA, making it unreliable as a screening or diagnostic tool.
Where CEA becomes valuable is after diagnosis and treatment. A baseline CEA level taken before surgery gives doctors a reference point. After treatment, CEA is typically checked every two to three months. A rising level can be one of the earliest signals that the cancer has come back, with about 80% sensitivity for detecting recurrence.
Putting the Pieces Together: Staging
All of these tests feed into a staging system that classifies the cancer from stage I (small, confined to the rectal wall) through stage IV (spread to distant organs). The “T” component describes tumor depth, “N” indicates lymph node involvement, and “M” marks distant metastasis. Staging determines everything that comes next: whether you need chemotherapy or radiation before surgery, what type of surgery is appropriate, or whether surgery is the right first step at all.
The full diagnostic workup, from initial colonoscopy through completed staging scans, usually takes one to three weeks. Your care team will typically wait until all results are in before presenting a treatment plan, because each piece of information influences the others. A tumor’s molecular profile, its distance from the anal opening, its relationship to the mesorectal fascia, and the presence or absence of distant spread all interact to shape the recommended approach.